Topic Hub
9 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 9 of 9 clinical reviews.
Evidence-based guide to eszopiclone dosing in East Asian populations, covering CYP3A4 pharmacogenomics, body-weight considerations, and clinical monitoring recommendations.
Read clinical reviewEvidence review of eszopiclone efficacy, pharmacogenomic variability, and dosing considerations for Black and African ancestry patients, with cited trial data and clinical guidance.
Read clinical reviewEvidence-based review of how eszopiclone (Lunesta) safety and pharmacogenomics differ in South Asian populations, including CYP3A4 metabolism, dosing considerations, and cardiovascular overlap.
Read clinical reviewA clinician-reviewed guide to eszopiclone pharmacokinetics, pharmacogenomics, and safety considerations specific to Black and African ancestry patients, including CYP3A4 variation, G6PD prevalence, hypertension drug interactions, and dosing guidance.
Read clinical reviewEast Asian patients metabolize eszopiclone (Lunesta) faster through CYP2C19 ultrarapid pathways, producing measurable efficacy gaps. Learn what the pharmacogenomic data show, how dosing should be adjusted, and what clinicians need to know before prescribing.
Read clinical reviewEast Asian patients metabolize eszopiclone (Lunesta) differently due to CYP2C19 poor-metabolizer rates up to 15%, raising exposure, next-day sedation risk, and dosing considerations. Learn the pharmacogenomic basis, recommended starting doses, and monitoring guidance.
Read clinical reviewA clinical deep-dive into eszopiclone (Lunesta) safety, dosing, and pharmacogenomics in Hispanic / Latino patients, including CYP3A4/5 variation, diabetes comorbidity risk, and FDA-label guidance.
Read clinical reviewAn evidence-based review of eszopiclone (Lunesta) efficacy differences in Hispanic / Latino patients, covering pharmacogenomics, CYP2C19 variants, diabetes co-morbidity, and dosing considerations.
Read clinical reviewEszopiclone (Lunesta) may work differently in South Asian patients due to CYP3A4/CYP2C19 variation, body-composition differences, and underrepresentation in key trials. This review covers the pharmacogenomic evidence, dose considerations, and clinical decision points.
Read clinical review